// App-Quantinova.ai

AB0431 (2021) : EXPLORING THE UTILITY OF THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CRISS IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

Researchers

Presenter

  • F. Del Galdo

Principal Investigators

  • O. Distler

  • C. Denton

  • Y. Allanore

  • D. Wachtlin

  • M. Alves

  • D. Khanna

Medical Centers

  • University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine and Biomedical Research Centre, Leeds, United Kingdom

  • University Hospital Zurich, Department of Neuropathology, Zurich, Switzerland

  • University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom

  • , Descartes University, APHP, Cochin Hospital, Department of Rheumatology A, Paris, Italy

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • University of Michigan Health System, Department of Internal Medicine, Ann Arbor, United States of America

Locations

  • United Kingdom

  • Switzerland

  • France

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Mycophenolic acid

  • Methotrexate

  • Nintedanib

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved